title: A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
abstract: The antiproliferative activities of wild-type (wt) p53 are inhibited by mdm2 (murine double minute2) oncogene product. We tested growth suppression activity of p53 14/19, an engineered p53 variant, which does not bind mdm2 and is completely resistant to the inhibition by mdm2. p53 14/19, unlike wt p53, suppressed the growth of cancer cells that contain amplified mdm2 oncogene efficiently by direct DNA transfection or adenovirus-mediated gene transfer. In addition, p53 14/19 also inhibited the growth of several different cancer cell lines expressing low levels of mdm2 oncogene product as efficiently as wt p53. We further examined the antioncogenic potencies of p53 14/19 in the rat embryo fibroblast cotransformation assay. Addition of wt p53 failed to cause any significant decrease in ras plus mdm2 foci counts. In contrast, cotransfection of p53 14/19 with ras and mdm2 significantly reduced foci number. In similar experiments, cotransfection of wt p53 or 14/19 p53 resulted in significant inhibition of oncogenic transformation in rat embryo fibroblast mediated by an activated ras plus c-myc, adenovirus E1A, or human papillomavirus E7 oncogenes. Therefore, these results suggest that p53 14/19 modified tumor suppressor gene may be a promising therapeutic agent for human cancers that express abnormally high levels of mdm2 oncogene product.
authors.affiliation: Department of Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA. linjia@umich.edu
authors.forename: J
authors.initials: J
authors.lastname: Lin
authors.forename: X
authors.initials: X
authors.lastname: Jin
authors.forename: C
authors.initials: C
authors.lastname: Page
authors.forename: V K
authors.initials: VK
authors.lastname: Sondak
authors.forename: G
authors.initials: G
authors.lastname: Jiang
authors.forename: R K
authors.initials: RK
authors.lastname: Reynolds
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D019943:Amino Acid Substitution; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D004247:DNA / Q000235:genetics; D005347:Fibroblasts / Q000378:metabolism / Q000502:physiology; D005784:Gene Amplification; D006131:Growth Inhibitors / Q000235:genetics; D006801:Humans; D009687:Nuclear Proteins; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D051736:Proto-Oncogene Proteins c-mdm2; D051381:Rats; D015533:Transcriptional Activation; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D006131:Growth Inhibitors; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D004247:DNA; C497206:MDM2 protein, human; C497208:Mdm2 protein, rat; D051736:Proto-Oncogene Proteins c-mdm2